Thrombocytopenia News and Research

RSS

Thrombocytopenia is a condition in which there is a lower-than-normal number of platelets in the blood. It may result in easy bruising and excessive bleeding from wounds or bleeding in mucous membranes and other tissues.

Risk factors for mortality among hospitalized patients with COVID-19

A new study by scientists at biotechnology company Genentech, Inc., and published on the preprint server medRxiv in September 2020 attempts to identify the factors which may shape the risk for death in COVID-19 disease.

27 Sep 2020

Antibody-mediated platelet death linked to COVID-19 severity

A new study by University of Tuebingen researchers shows the strong association between platelet apoptosis and the thrombotic manifestations that may underlie critical COVID-19 illness.

7 Sep 2020

Phase 3 study to test efficacy of new treatment for pediatric acute-onset neuropsychiatric syndrome

Octapharma has launched a phase 3, multi-center superiority study to compare the effectiveness of PANZYGA (immune globulin intravenous, human - ifas) 10% Liquid Preparation versus placebo in patients with pediatric acute-onset neuropsychiatric syndrome (PANS).

3 Sep 2020

SARS-CoV-2-RNA viremia is a robust marker of critical illness in COVID-19

A new study by a large team of Spanish researchers and published on the preprint server medRxiv* in August 2020 reports that the presence of viral RNA in the blood is a useful marker of impending acute disease and can help triage COVID-19 disease patients who will require hospital care.

1 Sep 2020

Cardiovascular disease in COVID-19

The current COVID-19 pandemic is a primarily respiratory illness, manifesting with severe hypoxia and often progressing to acute respiratory distress syndrome (ARDS) and death. However, it is also known to be linked to a wide range of cardiovascular (CV) manifestations that are associated with a very poor prognosis.

13 Aug 2020

Groundbreaking technology could enhance therapeutic efficiency of nanomedicines

Researchers from the Moscow Institute of Physics and Technology and their colleagues from Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry and Prokhorov General Physics Institute of the Russian Academy of Sciences have developed a breakthrough technology to resolve a key problem that has prevented the introduction of novel drugs into clinical practice for decades.

17 Jul 2020

New test uses a single drop of blood to rapidly detect radiation sickness

A new proof-of-concept study reports evidence that a new testing method has the potential to rapidly identify radiation sickness based on biomarkers measured through a single drop of blood.

15 Jul 2020

COVID-19 – researchers sum up the “Tsunami” of information

The severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection leading to COVID-19 is a raging pandemic across the world at present. It has infected 13 million and killed 571,000 individuals around the world as of today. The infection was first reported in Wuhan, Hubei Province of China in late December 2019.

13 Jul 2020

Clots, COVID-19 and survival

The novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that causes COVID-19 disease, was first reported in Wuhan, Hubei Province of China in late December 2019. Since then, it has infected a large population across the world with the current number of SARS-CoV-2 infections standing at over 13 million and COVID-19 disease having killed over 571,000 individuals.

13 Jul 2020

Repurposed drug for acute lung injury in COVID-19

Now, a new study addresses the possible use of an FDA-approved monoclonal antibody, called fostamatinib, a spleen tyrosine kinase inhibitor (SYK), to reduce the levels of mucin-1, a molecule associated with acute lung injury and acute respiratory distress syndrome (ARDS). People who have severe COVID-19 disease may develop ARDS.

2 Jul 2020

Adoptive T-cell therapy targeting MAGE-A4 achieves responses in patients with multiple solid tumors

The adoptive T-cell therapy ADP-A2M4, which is engineered to express a T-cell receptor (TCR) directed against the MAGE-A4 cancer antigen, achieved responses in patients with multiple solid tumor types, including synovial sarcoma, head and neck cancer and lung cancer, according to results from a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

29 May 2020

New preclinical study shows promise for treating necrotizing enterocolitis

Necrotizing enterocolitis (NEC), a rare inflammatory bowel disease, primarily affects premature infants and is a leading cause of death in the smallest and sickest of these patients.

6 May 2020

Majority of patients with mantle cell lymphoma may benefit from CAR T-cell therapy KTE-X19

A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy.

1 Apr 2020

Direct oral anticoagulant more effective in lowering risk of VTE after common orthopedic surgeries

The direct oral anticoagulant rivaroxaban dramatically cut the likelihood of serious venous thromboembolism (VTE) in people recovering from lower limb orthopedic surgery requiring immobilization in comparison with enoxaparin, another anticoagulant agent, according to research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

Lessons learned from three Singapore COVID-19 clusters

A study published in the journal The Lancet in March 2020 reports on three clusters of COVID-19 that happened in Singapore in February 2020. The first was because of a tour group, the second a company conference, and the third a church gathering.

17 Mar 2020

New antibody-drug conjugate shows promising activity in salivary gland tumors

The antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) has promising activity in HER2 amplified salivary gland tumors, according to data published in the Annals of Oncology.

7 Jan 2020

UTHealth scientist receives NIH grants for liver injury research

Tiny solutions are being sought for big liver problems by a scientist at McGovern Medical School at The University of Texas Health Science Center at Houston.

21 Dec 2019

Inhibition of a single enzyme may reduce heparin-induced thrombocytopenia

Heparin is widely used as an anticoagulant, but evokes in some patients a potentially life-threatening condition called HIT. Clinical scientists at Ludwig-Maximilians-Universitaet in Munich have now shown that inhibition of a single enzyme may markedly reduce this risk.

21 Dec 2019

New combination therapy can lead to durable responses in patients with multiple myeloma

An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.

17 Dec 2019

PARP inhibitor combined with chemotherapy increases survival for newly diagnosed ovarian cancer patients

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that initial treatment with the PARP inhibitor veliparib in combination with chemotherapy significantly increased progression-free survival for patients with newly diagnosed, metastatic high-grade serous ovarian cancer, according to the results of the VELIA trial.

28 Sep 2019